It has been suggested that hypertensive patients with raised aldosterone-to-renin ratio (Arr) are specifically sensitive to mineralocorticoid receptor antagonists (mrAs). We have previously shown that patients with an elevated Arr are relatively frequent in the setting of primary care. We therefore designed an interventional study to ascertain whether primary care hypertensive patients with an elevated Arr presented a superior response to mrA treatment than subjects with normal ratio.
In the past years, the traditionally quoted low prevalence of primary aldosteronism (PA) among persons with hypertension has been challenged. Several studies have indeed reported that at least 10% individuals, initially diagnosed as having essential hypertension, fulfill the biochemical criteria for PA. [1] [2] [3] [4] For example, a very recent study regarding >1,000 newly diagnosed hypertensive patients, referred to a large number of Italian hypertension centers, has shown an overall prevalence of PA >11%. 5 Most of these persons have mild hyperaldosteronism and do not have hypokalemia, thus they are clinically indistinguishable from individuals affected by essential hypertension. [1] [2] [3] [4] [5] This change in the estimated prevalence of PA has been mainly due to the widespread use of the "aldosterone-to-renin ratio" (ARR) as a screening test capable of detecting "inappropriately high" aldosterone secretion for the degree of reninangiotensin-aldosterone system activation. 3, 4 Although the individual components of this system may vary in different ways and to different extents, their reciprocal relationship should remain relatively constant under physiologically regulated conditions (i.e., sodium and potassium intake, dehydration, hypervolemia, circadian variation etc.). As a consequence, an elevated ARR suggests that the set point for regulation of the renin-angiotensin-aldosterone system has to be structurally altered in PA. An elevated ARR, however, is not sufficient for the diagnosis of PA that requires confirmation tests. Thus, when PA is not confirmed, this apparent abnormality in aldosterone regulation remains unexplained and is considered as a form of low-renin hypertension.
ARR elevation has also been reported as being a useful predictor of patient susceptibility to spironolactone treatment, articles Menopausal Hypertension and MR Antagonists regardless of the established diagnosis of PA. [6] [7] [8] Some authors have also provided evidence that a low plasma renin is a sufficient and simple way of detecting spironolactone-responders among patients with resistant hypertension. [9] [10] [11] Patients with elevated ARR, who do not meet the criteria for PA diagnosis, seem to develop hypertension resistant to the standard (i.e., not including mineralocorticoid receptor antagonists (MRAs)) drug treatment in proportion similar to that observed in PA patients. 11 Thus, the "spironolactone option" is generally recommended for patients with resistant hypertension or those requiring more than two agents for blood pressure (BP) control, 4,12 but a more generalized use of such drug-especially in the setting of primary care-is far to be well defined.
Although very few studies have attempted to define the costbenefit of ARR screening in the context of primary care, [13] [14] [15] available evidence shows that the prevalence of hypertension with inappropriate levels of aldosterone in the general population is similar to that observed in patients referred to specialist hypertension units. [13] [14] [15] Moreover, in the setting of primary care, patients with an elevated ratio, but diagnosed as not having PA on confirmatory testing, seem to be relatively numerous. 15 If these patients are relatively frequent, clinically indistinguishable from those with essential hypertension, and specifically sensitive to a low-cost therapy such as MRA, then ARR could be used as an useful predictor for selecting MRAresponders in primary care.
In 2004, with the collaboration of a number of general practitioners (GPs), we performed a population-based study to tackle the problem of defining the prevalence of patients with an elevated ARR in the setting of primary care. 14 In a sample of adults aged 35-74 years, randomly selected from the population register of the Bussolengo Health District (Northern Italy) and representative of the total district population, an elevated ARR was present in about one-third of the patients diagnosed as hypertensive. 14 On the basis of such result, we subsequently designed an interventional study to ascertain whether the patients, previously identified by an elevated ARR, presented a superior response to MRA treatment than subjects with normal ratio, independently of the established diagnosis of PA.
Methods
Patients selection. Details of patients selection have been previously described. 14 Briefly, a sample of adults (n = 1,462, aged 35-74 years), randomly selected from the general population register of Bussolengo health district and representative of the total population of the district (n = 124,991) in terms of age and sex distribution, educational status, and socioeconomic level, was examined by their GPs and diagnosed as hypertensive or not on the basis of well-established criteria. These criteria were:
1. Systolic BP (SBP) >140 or diastolic BP (DBP) >90 mm Hg, measured twice in both arms with a mercury sphygmomanometer using phase 5 for diastolic component, with the patient in the sitting position for 5 min, providing that he had not drunk any coffee or smoked during the previous 30 min; a third measurement (or further measurements, if necessary) was obtained in the case of a difference in BP values >5 mm Hg. To establish a firm diagnosis, high BP also had to be confirmed 2 weeks later (the same procedure was repeated as described above); or 2. Current therapy for a previous diagnosis of hypertension.
Of 412 hypertensive patients, 287 agreed to give blood for assay of hormones and other routinary biochemical parameters. Apart from verapamil or α-blockers, no hypotensive drugs were allowed during the 4 weeks prior to assay of upright active renin and aldosterone.
Biochemical assays. Plasma aldosterone was measured by a commercially available method, according to the manufacturer's instructions (Maia Adaltis, Italy), and expressed as pg/ml.
Renin was measured as direct active renin (pg/ml) by the Nichols Diagnostics chemiluminescent immune assay performed on the automated Nichols Advantage System. The intraassay and interassay variation coefficients were <5 and 8%, respectively.
All the other biochemical parameters were measured according routine methods.
Interventional study. Given that one-third of hypertensive patients presented an elevated ARR (i.e., >32 pg.ml -1 /pg.ml -1 ) at the previous screening, a similar proportion (1/3 with elevated ARR and 2/3 with low/normal ARR (nARR)) of patients was planned to be investigated in the interventional study. After hormonal assay, all patients were invited to participate in the study by their GPs, who were not informed about ARR values obtained before. For this reason, no patient underwent confirmatory tests for PA or was further examined in the Hospital. The only conditions required to be included in the study were: (i) the exclusion of adrenal masses by adrenal CT; (ii) kalemia <5.1 mmol/l or serum creatinine values <1.6 mg/dl; (iii) specific intolerance to MRA; and (iv) a negative pregnancy test in case of fertile women.
Although the totality of patients, previously identified as hypertensive in the "Bussolengo study, " 14 were invited to participate to the pharmacological trial, only 104 subjects accepted to sign informed consent and were finally included in the study.
An overview of the trial design is shown in Figure 1 . After a first clinical evaluation, patients entered on a 14-days run-in phase during which no hypotensive drugs were allowed or, if clinically necessary to avoid uncontrolled hypertension, "ARRneutral" agents such as verapamil and α-adrenergic blockers (doxazosin) were used or continued 7 according to the previously approved protocol. 14 The criteria for using such drugs were: SBP >160 mm Hg and/or DBP >110 mm Hg. Dosage, possible changes, and duration of such drug therapy was carefully recorded during all the study and BP variations were evaluated as differences from the basal values.
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After the run-in period when BP was serially checked, enrolled patients with either high ARR (hARR) or nARR values were treated with oral kanrenoate 50 mg/day and sequentially examined one and 2 months later according to scheduled visits (Figure 1) . At 1 week of treatment, serum electrolytes and creatinine were checked to exclude acute renal impairment and hyperkalemia. At every visit, relevant medical history, current medical conditions, possible drug adverse effects, physical examination, and careful (see above) BP measurement were obtained and recorded in a specific folder, previously sent by mail to the GPs. Serum electrolytes and creatinine values were also checked every time. Baseline BP was considered as the mean of the values recorded during the run-in period.
Background kanrenoate treatment was titrated at 100 mg/ day after the first month visit, according to the BP response and serum potassium values (if K + levels ≥5.5 mmol/l, patients were excluded).
An adequate BP response was considered when SBP <140 and DBP <90 mm Hg was obtained; in this case, kanrenoate dose was not further modified. If mean (of three measures) SBP and mean DBP values were <110 and <70 mm Hg, respectively, verapamil and α-blockers were withdrawn and kanrenoate continued unchanged during the second month of the study. In all the remaining cases, dose of kanrenoate was increased to 100 mg/day. To avoid any risk for the patients, addition of verapamil and/or α-blockers was allowed if SBP and DBP values were >160 and >110 mm Hg, respectively.
The entire study lasted 10-11 weeks for each patient. The primary outcome was to determine whether BP response after 2 months of MRA treatment was superior in hARR than in nARR patients. Considering clinically significant a MRAinduced difference between hARR and nARR patients of 8 and 15 mm Hg for DBP and SBP, respectively, the minimal sample size (90% power at 0.05 level of probability) was calculated to be at least 30 subjects per group.
The study was approved by the institutional review committee of Bussolengo Health District.
Statistical analysis. Data analysis was performed using the SPSS 13.0 for Windows (SPSS, Chicago, IL). Quantitative values were expressed as means ± s.d. Student's t-test for unpaired or paired observations or Mann-Whitney U test was used for normally or non-normally distributed variables, respectively. Qualitative data were analyzed by the χ 2 -test.
results
Previous selection, based on the demographic register, included a sex-balanced sample of the general population, 14 so that participants of the present study were also equally distributed by gender (50% female, 50% male). Of 104 patients initially recruited, only 90 (45 male, 45 female) completed the study. The remaining individuals missed the final check after 2 months of treatment, apparently for personal reasons because no drug-related adverse effects were recorded by their GPs; these subjects who did not conclude the trial were excluded from the final statistical computation.
No patient needed further treatment with verapamil and/ or α-adrenergic blockers to obtain an adequate BP control. In contrast, in a relevant proportion (n = 44, 49%) of patients, initial treatment included verapamil for 25 patients (16 of them 240 mg/day, the remaining 120 mg/day) or doxazosin for 24 patients (1 patient 8 mg/day, 16 patients 4 mg/day, 7 patients 2 mg/day), or both drugs for five patients; only in seven patients (7.8%), the dosage was reduced or drugs withdrawn during the trial.
In this way, considering the "null" hormone effect of the concomitant drugs, BP changes occurring in our patients were exclusively dependent on MRA treatment. In patients (n = 7) for whom verapamil and/or α-adrenergic blockers dosage was reduced or drugs withdrawn, MRA-dependent effect on BP was also considered in qualitative terms (reduced or unchanged BP with a reduced number of hypotensive drugs was considered as "improved BP control").
The main clinical features of the patients, subdivided according hARR or nARR, are summarized in Table 1 . The subgroups were substantially matched for all the variables but an elevated ARR was more frequent in female than in male gender. Baseline SBP was 145.6 ± 12 and 143.4 ± 13 mm Hg (P = nonsignificant (NS)) and baseline DBP was 88 ± 7 and 88.2 ± 8.6 mm Hg (P = NS) in women and men, respectively. Age was also similar in both genders (female 57.8 ± 8 years vs. male 55.1 ± 10 years, P = NS).
Although the difference did not reach statistical significance, there was much more menopausal women in hARR than in nARR group (90.5% vs. 75%). No hormone replacement therapy or other complimentary preparations were used by these patients. Postmenopausal period was similar in the groups (149 ± 69 months vs. 144 ± 80 months, NS).
Patients receiving or not receiving concomitant treatment with verapamil and/or doxazosin were also compared. No differences in distribution between hARR and nARR groups were observed for treatment with verapamil and/or α-adrenergic blockers at baseline before hormonal assay (58% vs. 44%, P = NS). No more hARR than nARR patients required add-on Overall, a clear reduction of BP values was recorded after both the first and the second month of treatment with kanrenoate, with the maximal effect obtained when the dosage titration at 100 mg/day was accomplished. However, unexpectedly, patients previously identified by an elevated ARR did not have a larger response to MRA treatment than patients with nARR ( Figure 2) . Differences between basal and 1-month or 2-month BP values were indeed neither statistically significant for systolic nor for diastolic BP components. After 2 months of MRA treatment, the primary outcome for DBP (≥8 mm Hg decrease from basal values) was obtained in 12 and 22 (37.5% vs. 37.9%, P = NS) patients of hARR and nARR subgroups, respectively. The primary outcome for SBP (≥15 mm Hg) was obtained in 18 and 26 (56.3% vs. 44.8%, P = NS) patients of hARR and nARR subgroups, respectively. Combined outcome (SBP ≥15 mm Hg or DBP ≥8 mm Hg decrease from basal values) was obtained in 56% of the whole population (60% of female patients, 51% of males) and in 55.2 and 56.3% of hARR and nARR patients, respectively. Also in qualitative terms (patients in whom hypotensive drugs were withdrawn or dosage reduced), the rate of improved BP control was not different between hARR and nARR participants.
In contrast, BP response was much more elevated in females than in males, and this difference reached statistical significance for SBP at both checks, that is after 1 and 2 months of kanrenoate treatment (Figure 3) ; difference for DBP did not reach statistical significance at any time.
When female gender was separately analyzed and menopause considered as a confounding factor, SBP response resulted relatively good in both normal and elevated ARR menopausal women (18.5 ± 13 and 14.6 ± 16 mm Hg, respectively), whereas a clearly higher SBP reduction was observed in two women with normal menstrual cycle who presented an elevated ARR as compared with six other fertile women with nARR (29.3 ± 15 mm Hg vs. 11.6 ± 10 mm Hg). No statistically significant difference in SBP or DBP response to MRA between men with hARR or nARR was observed (9.9 ± 20 mm Hg vs. 7.7 ± 15 mm Hg); in the same way, there was no correlation between SBP or DBP changes and ARR or aldosterone levels.
No significant adverse effects were recorded during the trial, and neither creatinine nor potassium values increased at clinically significant or dangerous levels, in particular mean 
discussion
The primary purpose of the present work was to verify whether patients, previously identified by an elevated ARR, have a superior response to MRA treatment than participants with normal ratio, independently of the established diagnosis of PA. If ARR may be used to identify hypertensive participants who respond well to treatment with MRA, current controversy 16, 17 concerning the cost and potential hazards of a generalized screening and subsequent workup for PA diagnosis could be defeated. The problem is particularly important in the setting of primary care, i.e., that examined in the present study. Because confirmatory suppression tests, possibly followed by adrenal venous sampling, are required to determine the subtype of PA, in particular to diagnose surgically curable aldosterone-producing adenomas, testing may not be practicable on the community-based level. At the end of the diagnostic workup, the majority of PA patients (i.e., those affected by bilateral adrenal hyperplasia) take MRAs, which are generally effective in controlling their BP and the related cardiovascular risk. 18 Moreover, the infrequency of adenomas suggests that the response to MRAs can be undertaken first as an "ex juvantibus" therapeutic test. Finally, not only an overt PA but also a raised ARR seems to represent by itself a marker of unfavorable cardiovascular conditions such as arterial stiffness, 19, 20 impairment of nitric oxide-mediated vasodilation of resistance vessels, 21 and subsequent development of resistant hypertension. 22 Despite all these favorable premises and some previous positive reports, 6-8 our results did not confirm the initial hypothesis and did not give support to the view of ARR as a marker able to predict a better response to MRA in primary care hypertensive patients. In a group of such patients, in which individuals with hARR were in the same proportion we found in the general population, 14 MRA treatment resulted to be highly but equally effective in subjects with or without a coexisting relative aldosterone excess as expressed by an elevated ARR.
Although the major limitation of the work is the relatively small sample size due to the poor adhesion of the original Bussolengo population, the statistical power of the study was sufficient to detect a difference of 8 and 15 mm Hg for DBP and SBP, respectively, from the basal BP values. We cannot exclude that a statistically significant result may be achieved for an inferior BP decrease in a larger sample of patients with or without an elevated ARR. This possibility requires to be further evaluated in an adequate study population.
However, for the same reason, if a statistical result was obtained with such limited sample size, the evidence that female gender represents an important factor in determining MRA response appears much more convincing. MRA was twofold more effective in reducing SBP in women than in men, both at early (1 month) and at later time (2 months of treatment) (Figure 3) .
A relevant proportion of patients was taking concomitant therapy (verapamil and/or doxazosin) to avoid uncontrolled hypertension. Although not statistically significant, a tendency toward a lower BP response was observed in these patients suggesting that, in case of all drug-naive patients, MRA effects may be even greater than those observed in our population.
Since the majority of recruited women was in menopause, we looked for dissecting the effects connected with this condition from those related to ARR. As previously reported in the original population of the "Bussolengo" study, 14 an elevated ARR was preferentially found (65%) in women >55 years. Similarly, in the present trial, females represented 65.6% of hARR individuals, and 90.5% of them were in menopause ( Table 1) . Since 75% of females in nARR group were also in menopause, it was difficult to separate the effects of ARR from those of the menopausal condition because of the relatively limited size of our sample. Indeed, no statistical difference in SBP or DBP response was observed by comparing menopausal women with raised and nARR.
Notably, two out of eight women with a normal menstrual flow had an elevated ARR and showed the largest SBP reduction (−29.3 mm Hg) after treatment, whereas the remaining six women with nARR presented a much more limited SBP response (11.6 ± 10 mm Hg). This could suggest that the predictive value of ARR may become evident only if the confounding effect of the menopause is lacking, but further specific studies are necessary to prove it.
As a further limitation, a placebo-controlled arm was not included in the study so that the observed BP changes could be theoretically discussed as placebo-related effects. This interpretation does not account for the statistically different response to MRA in the different subgroups of patients, all similarly treated with the same drug for 2 months, and already followed for longtime by their habitual practitioner. Moreover, GPs were not informed about ARR values obtained before, and each of them recruited a very limited number (range 1-5, mean 2) of patients. Such timing and procedural conditions should have minimized a possible placebo effect and eliminated the bias connected with an open-label study. In contrast, the results suggest a specific drug sensitivity among primary care patients sharing a very common clinical manifestation, that is, a mild hypertension without any apparent element of suspect for secondary forms. Actually, this study is not the classic comparison between different drugs in matched groups of subjects but a comparison between different subjects exposed to the same drug. Overall, the major result of the present study is that postmenopausal status, that is, estrogen or progestogen deficiency or both, is frequently associated with hypertensive mechanism(s) dependent on mineralocorticoid receptor activation and selectively sensitive to MRAs. Although an increased ARR has been preferentially associated with the female gender and menopausal status, 14, 23 to the best of our knowledge a substantial difference by gender in BP response to MRA has never been reported, and it has been an unexpected finding for us.
On average, our patients presented a 12-years-postmenopausal period but information about the onset of hypertension was unclear or lacking. For this reason, we were unable to ascertain whether women developed hypertension once they were postmenopausal or not. However, a long absence of female gonadal steroids was unquestionably a constant feature of all these patients.
Various humoral systems have been proposed to play a role in postmenopausal hypertension such as changes in estrogen/ androgen ratios, increases in endothelin and oxidative stress, and activation of the renin-angiotensin system, 24 but none of them may account for the specific drug sensitivity we observed. Lack of estrogens may lead to a maladaptive response to a sodium load and an activation of renin-angiotensin system, no more blunted by endogenous female hormones, has been claimed to contribute to the hypertension in menopausal status. 25 However, evidence that estrogens increase epithelial sodium channel mRNA at the collecting duct cell level 26 suggests that estrogens deficiency should have no obvious effects on pathways sensitive to MRAs.
In contrast, progesterone exerts a well-known antimineralcorticoid action and affects sodium and water balance by directly antagonizing the late distal mineralocorticoid receptor and by downregulating epithelial sodium channel. 25, 27 Lack of such inhibitory effects of progesterone may therefore favor an increased mineralocorticoid receptor activation and epithelial sodium channel activity.
Spironolactone and its metabolite kanrenoate bind to progesterone receptors, and the synthetic progestogen compound drospirenone with peculiar antimineralcorticoid activity has been demonstrated to be an excellent antihypertensive drug in menopausal women. [28] [29] [30] In relationship with the results of the present study, it is impressive to observe that 3 mg of drospirenone, which is considered to be equivalent to 25 mg of spironolactone, 31 reduced postmenopausal SBP by −8.5/−9 mm Hg and DBP by −4.2/5 mm Hg. [28] [29] [30] Thus, the lack of progesterone in menopausal women may overall affect also the balance between occupancy and functional engagement of MRs and progesterone receptors, favoring the mechanism finally leading to an increased and effective activation of epithelial sodium channel. The use of MRAs may reverse this unbalanced condition by means of a competitive inhibition on the target receptors.
From a therapeutic standpoint, the present results deserve some practical considerations. An important concern related to a larger use of MRAs is the theoretical potential for serious hyperkalemia, especially when renal insufficiency is also present. However, a similar concern has not prevented the current use of MRAs in heart failure patients, in whom MRA therapy has been proven to be highly effective. 32, 33 Check of renal function and potassium levels is a recognized practice in MRA-treated patients.
The major limitation with chronic use of MRAs is development of breast tenderness with or without breast enlargement, that is however largely dose-dependent. 34 Other common complaints are sexual dysfunction, particularly erectile dysfunction in men, and menstrual irregularities in women. Based on the data presented here, the choice of MRAs can be safely suggested to menopausal women, which are not susceptible to such side effects and represent a relevant part of the supposed target population.
Once validated by further controlled trials, this approach should prove highly cost-effective in terms of cardiovascular prevention and public health in women, taking into consideration the low cost of spironolactone or kanrenonate treatment.
